AI assistant
Sending…
Marker Therapeutics, Inc. — Director's Dealing 2016
Aug 25, 2016
35150_dirs_2016-08-25_2d7aca9a-5af6-40e7-8af5-da4ea3bf6901.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2016-08-25
Reporting Person: Loiacono Michael (Chief Financial Officer)
More from Marker Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Mar 20
Annual Report
2026
Mar 20
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 18
Regulatory Filings
2026
Feb 9
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Major Shareholding Notification
2025
Nov 17